| Literature DB >> 34104699 |
Samuel Bert Boadi-Kusi1, Samuel Kyei1, Selina Holdbrook1, Emmanuel Kwasi Abu1, Jonathan Ntow2, Abena Mantebea Ateko1.
Abstract
In developing countries such as Ghana, ophthalmia neonatorum (ON) remains a public health concern. This is because of its unknown etiology patterns, the growing concerns of antibiotic resistance strains and the contribution of ON to childhood blindness. This study was therefore conducted to determine the causative agents, risk factors and the antibiotic sensitivity patterns of micro-organisms associated with ON. A clinic-based prospective study was conducted in the Maternal and Child Health units of 6 health care facilities in the Central region of Ghana over a period of 17 months. Conjunctival swabs were taken from all neonates with clinical signs of ON. Isolation and characterization of bacteria were done using standard microbiological methods. Additionally, data were collected and analyzed on neonate's demographics and clinical features of ON. Microbial growth was recorded in 86 cases (52.4%) out of the 110 neonates assessed. Staphylococcus spp. (39.2% of all positive cultures) was the most common causative organism. No case of gonococcus was isolated. Delivery method, vaginal discharge, administration of prophylaxis and weight of neonate were the risk factors associated with the development of ON (P < .05). The level of resistance to Tetracycline was found to be 73%. Neonatal conjunctivitis is more likely to be acquired postnatal. Culture and sensitivity testing are required as an important guide for treatment. The commonest causative organism, Staphylococcus spp., were found to be resistant to Teteracyline, therefore is the need to consider alternatives measures in the prevention and control of ON.Entities:
Keywords: Antibiotic susceptibility; Neonatal conjunctivitis; Ophthalmia neonatorum; Postnatal; Staphylococcus
Year: 2021 PMID: 34104699 PMCID: PMC8165866 DOI: 10.1177/2333794X211019700
Source DB: PubMed Journal: Glob Pediatr Health ISSN: 2333-794X
Demographics and Clinical Manifestations of Neonates with ON.
| Variables | Frequency (n) | Percentage |
|---|---|---|
| Age of mothers (years) | ||
| 15-24 | 16 | 18.6 |
| 25-34 | 53 | 61.6 |
| 35-44 | 17 | 19.8 |
| Age of neonates (days) | ||
| 1-7 | 64 | 74.4 |
| 8-14 | 12 | 14.0 |
| 15-21 | 6 | 7.0 |
| 22-28 | 4 | 4.7 |
| Signs and symptoms | ||
| Discharge | 56 | 65.1 |
| Redness | 12 | 14.0 |
| Swollen eyelids | 4 | 4.7 |
| Tearing | 1 | 1.2 |
| Eye involvement | ||
| Unilateral | 57 | 66.3 |
| Bilateral | 29 | 33.7 |
Maternal and Neonatal Risk Factors Associated with ON.
| Variables | N% | |
|---|---|---|
| Gender | .702 | |
| Male | 52 (60.5) | |
| Female | 34 (39.5) | |
| Planned pregnancy | .855 | |
| Yes | 66 (76.7) | |
| No | 20 (23.3) | |
| Gestational period | .899 | |
| Pre-term <37 weeks | 6 (7.0) | |
| Full term >37 weeks | 80 (93.0) | |
| Mode of delivery | .035 | |
| Spontaneous Vertex Delivery (SVD) | 55 (64.0) | |
| Caesarian Section (CS) | 30 (34.9) | |
| Assisted delivery | 1 (1.2) | |
| Birth weight | .001 | |
| Low <2.5 | 3 (3.5) | |
| Normal ≥2.5 | 83 (96.5) | |
| Vaginal discharge | .028 | |
| Yes | 17 (19.8) | |
| No | 69 (80.2) | |
| Prophylaxis | .003 | |
| Given | 27 (31.4) | |
| Not given | 59 (68.6) | |
Frequency of Microorganism Isolates.
| Bacteria | Frequency | Percentage |
|---|---|---|
|
| 38 | 39.2 |
|
| 6 | 6.2 |
|
| 6 | 6.2 |
|
| 4 | 4.1 |
|
| 1 | 1.0 |
|
| 3 | 3.1 |
|
| 13 | 13.4 |
|
| 5 | 4.7 |
|
| 3 | 5.2 |
|
| 17 | 17.5 |
|
| 1 | 1.0 |
Antimicrobial Susceptibility Testing Showing Bacteria that were Resistance to Commonly Used Antibiotics.
| Resistance (%) | |||||||
|---|---|---|---|---|---|---|---|
| Antibiotics | TET | ERY | CIPRO | CHL | GEN | AMP | PEN |
| Disk content | (10 μg) | (5 μg) | (5 μg) | (10 μg) | (10 μg) | (10 μg) | (1.5 μg) |
| Bacteria | |||||||
| | 30 (77.8) | 16 (11.1) | 2 (0.0) | — | 1 (0.0) | 38 (100) | 38 (100) |
| | 4 (66.7) | — | 1 (16.7) | — | 0 (0.0) | 6 (100) | 6 (100) |
| | 4 (75.0) | — | 3 (66.7) | 3 (50.0) | 1 (16.7) | 6 (100) | 6 (100) |
| | 3 (75.0) | 4 (100) | 3 (75.0) | — | 3 (75.0) | 2 (50.0) | 3 (75.0) |
| | 1 (100) | 1 (100) | 0 (0.0) | — | 0 (0.0) | 1 (100) | 1 (100) |
| | 3 (100) | 3 (100) | 2 (66.7) | 3 (100) | 3 (100) | 3 (100) | 3 (100) |
| | 13 (100) | — | 9 (69.2) | 11 (84.6) | 8 (61.5) | 13 (100) | 13 (100) |
| | 3 (60.0) | — | 0 (0.0) | 1 (20.0) | 0 (0.0) | 4 (80.0) | 4 (80.0) |
| | 2 (100) | — | 2 (100) | 2 (100) | 2 (100) | 2 (100) | — |
| | 10 (58.8) | 13 (76.5) | 7 (41.2) | — | 5 (29.4) | 17 (100) | 17 (100) |
| | — | — | 0 (0.0) | — | 0 (0.0) | — | — |
| Total | 73 (75.3) | 37 (38.1) | 29 (29.9) | 10 (10.3) | 23 (23.7) | 92 (94.8) | 91 (93.8) |
Abbreviations: TET, tetracycline; ERY, erythromycin; CIPRO, ciprofloxacin; CHL, chloramphenicol; GEN, gentamycin; AMP, ampicillin; PEN, penicillin.
Antimicrobial Susceptibility Testing Showing Bacteria that were Susceptible to Commonly Used Antibiotics.
| Susceptibility (%) | |||||||
|---|---|---|---|---|---|---|---|
| Antibiotics | TET | ERY | CIPRO | CHL | GEN | AMP | PEN |
| Disk content | (10 μg/30 μg) | (5 μg) | (5 μg) | (10 μg) | (10 μg) | (10 μg) | (1.5 μg) |
| Bacteria | |||||||
| | 8 (21.1) | 22 (57.9) | 36 (94.7) | — | 37 (97.4) | 0 (0.0) | 0 (0.0) |
| | 2 (33.3) | — | 5 (83.3) | — | 6 (100) | 0 (0.0) | 0 (0.0) |
| | 2 (33.3) | — | 3 (50.0) | 3 (50.0) | 6 (100) | 0 (0.0) | 0 (0.0) |
| | 1 (25.0) | 0 (0.0) | 1 (25.0) | 2 (50.0) | 1 (25.0) | 2 (50.0) | 1 (25.0) |
| | 0 (0.0) | 0(0.0) | 1 (100) | — | 1 (100) | 0 (0.0) | 0 (0.0) |
| | 0 (0.0) | 0 (0.0) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| | 0 (0.0) | — | 4 (30.8) | 1 (7.7) | 5 (38.5) | 0 (0.0) | 0 (0.0) |
| | 2 (40.0) | — | 5 (100) | 3 (60.0) | 5 (100) | 1 (20.0) | 1 (20.0) |
| | 1 (33.3) | — | 1 (33.3) | 0 (0.0) | 1 (33.3) | 0 (0.0) | — |
| | 7 (41.2) | 4 (23.5) | 10 (58.8) | — | 12 (70.6) | 0 (0.0) | 0 (0.0) |
| | — | — | 1 (100) | — | 1 (100) | — | — |
| Total | 23 (23.7) | 26 (26.8) | 68 (70.1) | 9 (9.3) | 75 (77.3) | 3 (3.1) | 2 (2.1) |
Abbreviations: TET: tetracycline; ERY, erythromycin; CIPRO, ciprofloxacin; CHL, chloramphenicol; GEN, gentamycin; AMP, ampicillin; PEN, penicillin.